Cargando…
Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease that gradually impairs cognitive functions. Recently, there has been a conceptual shift toward AD to view the disease as a continuum. Since AD is currently incurable, effective intervention to delay or prevent pathological cognitive declin...
Autores principales: | Yu, Xianfeng, Shao, Kai, Wan, Ke, Li, Taoran, Li, Yuxia, Zhu, Xiaoqun, Han, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106168/ https://www.ncbi.nlm.nih.gov/pubmed/36914945 http://dx.doi.org/10.1097/CM9.0000000000002566 |
Ejemplares similares
-
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
por: Wang, Xiaoqi, et al.
Publicado: (2020) -
The preservation of right cingulum fibers in subjective cognitive decline of preclinical phase of Alzheimer’s disease
por: Sun, Yu, et al.
Publicado: (2023) -
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2023) -
The Impact of Study Setting on Clinical Characteristics in Older Chinese Adults with Subjective Cognitive Decline: Baseline Investigation of Convenience and Population-Based Samples
por: Zhao, Mingyan, et al.
Publicado: (2021) -
Subjective Cognitive Decline as a Preclinical Marker for Alzheimer's Disease: The Challenge of Stability Over Time
por: Ávila-Villanueva, Marina, et al.
Publicado: (2017)